Key facts
- Myrtelle’s last known valuation is $134.0M (Dec 2022).
- It has raised $82.6M across 4 recorded rounds; the latest was Early Stage VC ($30.5M) in Dec 2025.
- Notable investors include Panacea Venture, F1 BioVentures, Panacea Capital (California).
- Myrtelle has filed 4 Form Ds with the SEC since 2021, most recently Mar 2025 ($7.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Myrtelle
Funding rounds
4 roundsAbout Myrtelle
Operator of a gene therapy company intended to offer innovative clinical trials for the treatment of the rare monogenic disorder. The company helps to address an array of diseases with white matter involvement, including demyelinating diseases and ASPA-associated disorders with rare CNS diseases, enabling healthcare professionals to develop and deliver novel treatments for devastating disorders of the central nervous system and transform the treatment of neurological diseases that improve the quality of life and longevity.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 13
- Website
- myrtellegtx.com/
- Ownership
- Privately Held (backing)
Myrtelle doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myrtelle shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myrtelle in its N-PORT filings yet. We sweep new filings monthly.